Arrowhead Pharmaceuticals, Inc. (ARWR)
70.90
+3.30
(+4.88%)
USD |
NASDAQ |
Jan 22, 10:51
Arrowhead Pharmaceuticals Cash from Investing (Quarterly): 72.62M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 232.40M |
| Eli Lilly & Co. | -2.983B |
| Ionis Pharmaceuticals, Inc. | 91.34M |
| Cidara Therapeutics, Inc. | -176.47M |
| Celcuity, Inc. | -257.61M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 20.49M |
| Cash from Financing (Quarterly) | 3.669M |
| Free Cash Flow | 156.89M |
| Free Cash Flow Per Share (Quarterly) | 0.0958 |
| Free Cash Flow to Equity (Quarterly) | -7.393M |
| Free Cash Flow to Firm (Quarterly) | 22.68M |
| Free Cash Flow Yield | 1.66% |